TY - JOUR
T1 - Diagnosis, treatment and prevention of infective endocarditis
T2 - Turkish consensus report-2019
AU - Yavuz, Serap Şimşek
AU - Akar, Ahmet Rüçhan
AU - Aydoğdu, Sinan
AU - Deniz, Denef Berzeg
AU - Demir, Hakan
AU - Hazırolan, Tuncay
AU - Özatik, Mehmet Ali
AU - Özer, Necla
AU - Sargın, Murat
AU - Topcuoğlu, Emine Nursen
AU - Turhan, Nesrin
AU - Yılmaz, Mehmet Birhan
AU - Azap, Özlem
AU - Başaran, Seniha
AU - Çağ, Yasemin
AU - Çağatay, Atahan
AU - Çınar, Güle
AU - Kaya, Sibel Doğan
AU - Hızmalı, Lokman
AU - Işık, Mehmet Emirhan
AU - Kılıçaslan, Nirgül
AU - Menekşe, Şirin
AU - Meriç-Koç, Meliha
AU - Öztürk, Serpil
AU - Şensoy, Ayfer
AU - Tezer-Tekçe, Yasemin
AU - Tükenmez-Tigen, Elif
AU - Uygun-Kızmaz, Yeşim
AU - Velioğlu-Öcalmaz, Mutlu Şeyda
AU - Yeşilkaya, Ayşegül
AU - Yılmaz, Emel
AU - Yılmaz, Neziha
AU - Yılmaz-Karadağ, Fatma
N1 - Publisher Copyright:
© 2020 Turkish Society of Cardiology.
PY - 2020
Y1 - 2020
N2 - Infective endocarditis (IE) is a rare but still important as an infectious disease due to high rate of morbidity and substantial mortality. Although IE is not a notifiable disease in Turkey, and an incidence study has not been performed, the incidence may be higher than that in the developed countries due to frequent predisposing cardiac conditions and higher rates of nosocomial bacteremia, which may lead to IE in risk groups. IE generally affects the elderly in developed countries but it is frequently encountered among young individuals in Turkey. In order to reduce mortality and morbidity, it is critical to diagnose IE, to determine the causative agent, and to start treatment rapidly. Most patients cannot be diagnosed at the first visit, about half can be diagnosed after 3 months, and the disease often goes unnoticed. In patients diagnosed with IE, the rate of the identification of a causative organism is significantly lower in Turkey than that in developed countries. Some important microbiological diagnostic tests are not performed in most centers and several antimicrobials that are recommended as the first option for the treatment particularly antistaphylococcal penicillins, are unavailable in Turkey. These problems necessitate reviewing the epidemiological, laboratory, and clinical characteristics of IE in our country, as well as the current information about its diagnosis, treatment, and prevention together with local data. The diagnosis and treatment processes of IE should be standardized at every stage so that the management can be conducted in a setting in which physicians of various specialties are involved and is consistent with the current recommendations. The Study Group for Infective Endocarditis and Other Cardiovascular Infections of the Turkish Society of Clinical Microbiology and Infectious Diseases called for the collaboration of the relevant specialist organizations to establish a consensus report on the diagnosis, treatment, and prevention of IE in the context of current information and local data in Turkey.
AB - Infective endocarditis (IE) is a rare but still important as an infectious disease due to high rate of morbidity and substantial mortality. Although IE is not a notifiable disease in Turkey, and an incidence study has not been performed, the incidence may be higher than that in the developed countries due to frequent predisposing cardiac conditions and higher rates of nosocomial bacteremia, which may lead to IE in risk groups. IE generally affects the elderly in developed countries but it is frequently encountered among young individuals in Turkey. In order to reduce mortality and morbidity, it is critical to diagnose IE, to determine the causative agent, and to start treatment rapidly. Most patients cannot be diagnosed at the first visit, about half can be diagnosed after 3 months, and the disease often goes unnoticed. In patients diagnosed with IE, the rate of the identification of a causative organism is significantly lower in Turkey than that in developed countries. Some important microbiological diagnostic tests are not performed in most centers and several antimicrobials that are recommended as the first option for the treatment particularly antistaphylococcal penicillins, are unavailable in Turkey. These problems necessitate reviewing the epidemiological, laboratory, and clinical characteristics of IE in our country, as well as the current information about its diagnosis, treatment, and prevention together with local data. The diagnosis and treatment processes of IE should be standardized at every stage so that the management can be conducted in a setting in which physicians of various specialties are involved and is consistent with the current recommendations. The Study Group for Infective Endocarditis and Other Cardiovascular Infections of the Turkish Society of Clinical Microbiology and Infectious Diseases called for the collaboration of the relevant specialist organizations to establish a consensus report on the diagnosis, treatment, and prevention of IE in the context of current information and local data in Turkey.
KW - Consensus report
KW - Infective endocarditis
UR - https://www.scopus.com/pages/publications/85081683228
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=performanshacettepe&SrcAuth=WosAPI&KeyUT=WOS:000519250400018&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.5543/tkda.2020.89689
DO - 10.5543/tkda.2020.89689
M3 - Review article
C2 - 32147661
AN - SCOPUS:85081683228
SN - 1016-5169
VL - 48
SP - 187
EP - 226
JO - Turk Kardiyoloji Dernegi Arsivi
JF - Turk Kardiyoloji Dernegi Arsivi
IS - 2
ER -